E. Orlova-Morozova

Ledipasvir–Sofosbuvir for 8 Weeks in Non-Cirrhotic Patients with Previously Untreated Genotype 1 HCV Infection ± HIV-1 Co-Infection

D. Brainard, E. Svarovskaia, A. Osinusi, 2018, Clinical Drug Investigation.

International Congress of Drug Therapy in HIV Infection 23-26 October 2016, Glasgow, UK

Raúl Tabarés Gutiérrez, Samit R. Joshi, H. Jessen, 2016, Journal of the International AIDS Society.

Pregnancy and treatment interruption enhances progression of HIV‐infection if initial CD4+ T‐lymphocyte count is less than 700 cells/mm3

A. Pronin, E. Orlova-Morozova, G. Kaminskiy, 2012 .

Efficacy and safety of novel russian non-nucleoside reverse transcriptase inhibitor elsulfavirine in combination with 2 nucleoside/nucleotide reverse transcriptase inhibitors in first-line HIV treatment – 96-week study

V. Pokrovsky, O. Kozyrev, A. Popova, 2018, Journal Infectology.